help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2004-0712
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bozec, A.
Right arrow Articles by Mauduit, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bozec, A.
Right arrow Articles by Mauduit, C.
Related Collections
Right arrow Male Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 1 17-25
Copyright © 2005 by The Endocrine Society

Activation of Caspases-3, -6, and -9 during Finasteride Treatment of Benign Prostatic Hyperplasia

Aline Bozec1, Alain Ruffion1, Myriam Decaussin, Jean Andre, Marian Devonec, Mohamed Benahmed and Claire Mauduit

Institut National de la Santé et de la Recherche Médicale (U 407) (A.B., J.A., M.B., C.M.), Faculté de Médecine, Lyon-Sud, 69921 Oullins, France; Service d’Urologie (A.R., M.Dev.), Bat 2F, Centre Hospitalier Lyon-Sud, 69495 Pierre Bénite, France; and Service d’Anatomie et Cytologie Pathologiques (M.Dec.), Centre Hospitalier Lyon-Sud, 69495 Pierre-Bénite, France

Address all correspondence and requests for reprints to: Dr. Claire Mauduit, Institut National de la Santé et de la Recherche Médicale U 407, Faculté de Médecine Lyon-Sud, BP 12, 69921 Oullins Cedex, France. E-mail: mauduit{at}grisn.univ-lyon1.fr.

Benign prostatic hyperplasia (BPH) results from an increase in both epithelial and stromal compartments of the human prostate. Although inhibitors of 5{alpha}-reductase such as finasteride have been shown to reduce the size of BPH tissues by inducing apoptosis, their mechanisms of action still remain unknown. The present study supports that such a process triggered by finasteride is caspase dependent with a possible involvement of two effector caspases (caspase-3 and 6) and two initiator caspases (caspase-8 and 9). Indeed, by using tissues from patients affected by BPH and treated by finasteride (5 mg/d) for 2–3, 6–8, or 27–32 d, we observed that the 5{alpha}-reductase inhibitor induced apoptosis in epithelial cells (evaluated through cell number positive for terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) as early as 2–3 d of treatment, with a maximal activity (250-fold increase, P < 0.0001) at 6–8 d of treatment. However, after 27–32 d of treatment, the number of apoptotic cells was reduced and was close to control. Caspases-3, -6, -8, and -9 were immunolocalized to (basal and secretory) epithelial cells and to a lesser extent to stromal cells. Activated caspase-3 immunoexpression was restricted to epithelial secretory cells, and its immunostaining intensity appeared to be higher in BPH tissues from patients treated for 2–3 or 6–8 d. Consistently, in Western blotting analyses, activated caspases-3 and -6 were detected as early as 2–3 d of treatment in BPH tissues, and their levels were increased after 6–8 d of treatment. In real time quantitative PCR experiments, caspase-3 and -6 mRNA levels were found to be unchanged after finasteride treatment. Activated caspase-8 was not detected in the different conditions tested, whereas activated caspase-9 protein levels were maximally enhanced after 2–3 d of finasteride treatment. In conclusion, we report here that finasteride treatment of BPH tissues induced a caspase-dependent apoptotic process restricted to epithelial cells by activating effector caspases-3 and -6 and exhibited a transient action because the apoptotic process was no longer observed after 27–32 d of treatment.




This article has been cited by other articles:


Home page
Cancer Prevention ResearchHome page
J. Li and J. Kim
Molecular Profiles of Finasteride Effects on Prostate Carcinogenesis
Cancer Prevention Research, June 1, 2009; 2(6): 518 - 524.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
S. M. Ruwanpura, R. I. McLachlan, K. L. Matthiesson, and S. J. Meachem
Gonadotrophins regulate germ cell survival, not proliferation, in normal adult men
Hum. Reprod., February 1, 2008; 23(2): 403 - 411.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. M. Adhami, A. Malik, N. Zaman, S. Sarfaraz, I. A. Siddiqui, D. N. Syed, F. Afaq, F. S. Pasha, M. Saleem, and H. Mukhtar
Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both In vitro and In vivo
Clin. Cancer Res., March 1, 2007; 13(5): 1611 - 1619.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. T. Page, D. W. Lin, E. A. Mostaghel, D. L. Hess, L. D. True, J. K. Amory, P. S. Nelson, A. M. Matsumoto, and W. J. Bremner
Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3850 - 3856.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society